Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

February 20, 2020

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 76 min

Earnings Call Speaker Segments

Jake Elguicze

executive
#1

Hello everybody, and thanks for joining us on the Teleflex Incorporated fourth quarter 2019 earnings conference call this morning. You can find the press release along with the slides that go with this call on our website, www.teleflex.com. Just a reminder that this call is being made available on our website. If you'd like to hear a replay, you can dial 855 to 859 to 2056, or if you're calling internationally, 404 to 537 to 3406, and the passcode is 5857007. On the line with us today are Liam Kelly, our President and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom are going to give prepared remarks. After that, we'll open things up for Q&A. Before we get started, I want to remind everyone that a number of the matters we'll discuss on this conference call will include forward-looking statements about future events, as described in our slides; we want to caution you that those statements are indeed forward-looking in nature and are subject to risks and uncertainties, and actual events or results may differ materially. Among the factors that could cause actual results or events to differ materially are, but are not limited to, those referenced in our press release today, as well as our filings with the SEC, including our Form 10-K, which you can access on our website. Having said that, I'd now like to hand the call over to Liam.

Liam Kelly

executive
#2

Thanks, Jake. Morning, all — great to be with you today. For Teleflex, the fourth quarter of 2019 wrapped up a terrific year. In Q4, we delivered constant currency revenue growth in the upper single digits once again, and at the same time posted our best adjusted growth and operating margins since the company became a pure-play medical device business. Fourth quarter revenues rose 7.1% in constant currency terms. As was true across the first nine months of the year, our top-line strength in Q4 came from a wide range of areas, including growth of 64.4% in interventional urology, 6% in interventional access, and 4.6% in vascular access. Geographically, we saw especially robust growth in the Americas, where constant currency revenue growth reached 11.7%. Q4 constant currency revenue growth also got a lift from one extra selling day. That benefit, though, was offset by a headwind tied to the shutdown during the quarter of a facility belonging to one of our third-party sterilization providers. Looking at the full year, 2019 marked year one of our three-year long-range plan, and I'm happy that we surpassed our LRP constant currency revenue growth expectations. Our interventional urology business expanded by roughly 48%, our interventional access business by roughly 10%, and our OEM business by roughly 8%, while our vascular access and surgical businesses each expanded by roughly 6%. In addition, during 2019 we were able to proactively accelerate investment spending that we believe will deliver returns in the years ahead. Finally, we ended the year with an adjusted gross and operating margin profile that gives us confidence in our capacity to hit the long-range targets we previously provided. As we move into year two of our LRP, we remain confident in our ability to produce meaningful constant currency revenue growth, margin expansion, and adjusted earnings per share growth. Last, I'm happy to report that on February 18th, we closed our acquisition of privately held IWG High Performance Conductors, Inc., or HPC, a leading industry manufacturer of highly engineered, minimally invasive medical solutions. HPC should be accretive to our constant currency revenue growth rate and our adjusted operating margins. Importantly, we also expect this deal to be accretive to our Full Year 2020 adjusted earnings per share. With that overview in place, let's now dig into quarter four revenue in more detail. I'll start by reviewing revenues for our reportable segments. Unless I note otherwise, the growth rates I mention are on a constant currency basis. In the fourth quarter, the Americas posted revenues of $400 million, up 11.7%. This was fueled by our interventional urology, surgical, interventional access, and vascular access product categories. For the full year, the Americas grew 10.6%. Turning to EMEA. Fourth quarter revenues there were $145.9 million, down 0.6%. The drop in EMEA revenue stemmed in part from the timing and phasing of certain distributor orders. For the entire year, EMEA posted growth of 2.7%. Now looking at Asia, fourth quarter revenues came to $80.5 million, marking a 2.7% rise. If we look at it by product, the strongest gains came from our interventional access and anesthesia categories. Geographically speaking, our China business was up 8.5%; that was partly offset by softness in Australia, New Zealand, and India. For the full year, Asia was up 6.8%, with China leading the way at 11.5% growth. And finally, our OEM business posted fourth quarter revenues of $54.6 million, an increase of 4.3%. For the full year, our OEM business grew 8.2%. Let me now turn to discussing revenue by global product category. Just like what I said about our reportable segments, what I say about global product category growth will also be on a constant currency basis. Let's begin with vascular access. Fourth quarter revenues were up 4.6%, reaching $154.6 million. The drivers there were growth in PICC and EZ-IO; now on to interventional access. Fourth quarter revenue came in at $112.7 million, an increase of approximately 6%. Growth was broad-based, driven by higher sales in complex catheters, biologics, OnControl, and MANTA. That was partly offset by the divestiture of our catheter reprocessing product line, which had an exceptionally strong fourth quarter of 2018. Now turning to anesthesia. Fourth quarter revenue was $85.3 million, a decrease of 1.3%. The main reason was a modest pullback in purchasing patterns among U.S.-based distributors. Shifting over to our surgical business. Revenue rose 3.9% to $95.2 million. That revenue gain came from sales of ligation clips. Moving on to interventional urology. Fourth quarter revenue jumped a robust 54.4% to $89.1 million; that was a fantastic quarter, especially when you consider it was up against a very difficult comparable. Our sales force keeps making excellent progress in driving physician adoption of the UroLift System, and we finished the year having trained in excess of 500 new urologists, surpassing our goal of training 450 new urologists. Since inception, we have trained over 20% of the 12,000 U.S.-based urologists, and with an expectation that we will train at least 500 new urologists during 2020, we intend to start a piloted national direct consumer campaign as we progress through the year. We believe this campaign will further help create awareness of the UroLift System and will help establish UroLift as a standard of care for treating BPH. Moving to UroLift 2, we still expect to begin the UL2 rollout during the first half of this year. Lastly, since OEM was summarized as fourth quarter revenue for the businesses within our other category, which is made up of our respiratory and urology care products. Revenues there declined 4.2%, totaling $89.4 million. Even with a rather robust flu season, these product categories were down versus the prior year, mainly because of the sterilization issue I mentioned earlier. That wraps up what I had to say about how revenue performed in quarter four. Now I'd like to spend a short while on the label expansion we received not long ago for UroLift. In January, the FDA gave the UroLift system a broader indication, clearing it for use in treating prostates that are larger, specifically those weighing between 80 and 100 grams. The data set we submitted to the FDA showed that treating men with larger prostates using the UroLift system is both safe and effective, and that results seen in these patients mirror those from the pivotal LIFT randomized control trial. This additional indication represents yet another thrilling milestone, and it opens the door for hundreds of thousands of additional men to gain the benefits of the UroLift System, along with the durable, long-lasting relief it offers with no risk of sexual dysfunction whatsoever. Last, before handing things to Tom, let me take a moment to bring you up to speed on the acquisition we made public this morning. We acquired HPC on February 18th for $260 million. HPC holds a leading market position in insulated ultra-fine wires along with polyimide micro diameter tubing components, and it will be folded into our OEM segment. Through this acquisition, we gain two highly complementary and differentiated capability platforms, covering ultra-fine wire and tubing components used in therapeutic applications across fast-growing markets like electrophysiology, peripheral management, and pain management. Our OEM business also gains, through this deal, a platform featuring ultra-fine wire components for conducting electricity in healthcare applications. We're glad we were able to complete this acquisition, since it should prove accretive to our constant currency revenue growth rate as well as our adjusted operating margin profiles, in both the near term and over the longer haul. It should also be accretive to our adjusted earnings per share starting in 2020. To close, let me restate how happy we were with how we performed in the first year of our long-range plan. Revenue growth came in above what we had initially expected, powered by a wide array of products and geographies. On the bottom line, our adjusted earnings per share grew at more than double the rate of our as-reported revenue growth. Having now finished year one of our three-year LRP, we feel good about our capacity to hit the targets set out in May of 2018. I want to thank our employees and management teams for executing so well and for staying focused on achieving our goals. That's the end of my prepared remarks. I'd now like to hand the call to Tom, who will walk through our fourth quarter financial results and Full Year 2020 financial guidance in greater detail. Tom?

Thomas Powell

executive
#3

Thank you, Liam. Good morning to all of you. Since we've already covered how the company performed on revenue, I'll pick things up at the gross profit line. Adjusted gross profit for the quarter came in at $403.2 million, compared with $369.3 million during the same quarter a year earlier — a rise of roughly 9.2%. Adjusted gross margin widened 160 basis points against the prior-year period, hitting a record 59.2%. That improvement in adjusted gross margin mainly comes from higher sales volumes, a beneficial mix of products carrying larger margins — among them UroLift, vascular and interventional access — gains from footprint restructuring programs, and positive net pricing. Adjusted operating profit reached $184.5 million, against $169.9 million a year earlier, which works out to growth of about 8.5%. Adjusted operating margin climbed 60 basis points year over year, arriving at 27.1%, which is likewise a record high. Continuing further down the income statement, net interest expense fell to $16.8 million, compared with $23.1 million in the same quarter last year. This lower interest expense largely stems from the effect of our cross-currency swap agreements. Now on to taxes. Our GAAP effective tax rate for the fourth quarter stood at negative 6.4%, reflecting a discrete tax benefit that arose from remeasuring the applicable deferred tax assets and liabilities after a non-U.S. legal entity restructuring, which was undertaken because of a foreign tax law change taking effect on 1st January 2020. On an adjusted basis, the fourth quarter tax rate was 7.7%, versus 11.7% a year earlier; that brings me to adjusted earnings per share for the fourth quarter of 2019, which came to $3.28, an 18.4% rise over the prior year. Let me now turn to a few balance sheet and cash flow highlights. Cash flow from operations for 2019 came to $437.1 million, which is $2 million more than the previous year. That gain in operating cash flow is mostly due to favorable operating results, partly offset by the net unfavorable effect of working capital changes and $26.1 million in contingent consideration payments. If we normalize for those contingent consideration payments, operating cash flow would have risen by about 6.5%. Now for debt and leverage. In the fourth quarter, we brought down debt outstanding by roughly $90 million, and net leverage at year-end stood at approximately 2.4x. Once the HPC acquisition closes, our pro forma net leverage would be about 2.7x. Finally, during the fourth quarter the company finished redeeming its previously outstanding $250 million of 5.25% senior notes due in 2024. Although this transaction is leverage neutral, it will help 2020 through lower interest expense. It was funded by borrowings on the revolver; all in all, 2019 proved a very successful year for Teleflex. We twice raised our constant currency revenue growth expectations, and ultimately delivered revenue growth of 8.1%. On the earnings side, adjusted EPS came in at $11.15, up 12.6%; it's gratifying that we managed to lift guidance mid-year and ultimately post full-year earnings above the raised forecast. That beat felt especially good because achieving it meant overcoming a currency drag roughly double what we'd originally anticipated, along with heavier-than-expected China tariffs and an unexpected problem at a third-party sterilization vendor. That wraps up what I have to say about Q4 and full year 2019. Now on to 2020 guidance: for next year, we're projecting constant currency revenue growth in the 7.2% to 8.2% range. Within that figure, about 1.2% of growth stems from the HPC acquisition. Strip out that deal, and our constant currency revenue growth projection is 6% to 7%, with interventional urology, interventional access, and vascular access serving as the main growth drivers. On UroLift specifically, we're looking for revenue to rise no less than 25% versus 2019 levels; our 2020 guidance bakes in a 70 basis point FX headwind, hitting hardest in Q1 and Q2. Consequently, as-reported revenue should grow 6.5% to 7.5% in 2020, which works out to somewhere between $2.764 billion and $2.79 billion. Sterilization disruptions are also assumed to cut into first-half 2020 revenue to the tune of $5 million to $7 million. And finally, guidance incorporates a China revenue headwind from the coronavirus of $5 million to $10 million, roughly 5% to 10% of our full-year China business. That figure presumes Chinese life is back to normal come the start of April. Given how fluid things are, though, this estimate could shift as we learn more. Now for gross margin. Through 2020, we expect adjusted gross margin to climb 65 to 115 basis points, landing in a range of 58.75% to 59.25%; the expansion should come mainly from favorable mix of high-growth, high-margin products — interventional urology, interventional access, and vascular access among them — plus ongoing savings from footprint restructuring programs we've already announced. Next, adjusted operating margin. For 2020, we anticipate adjusted operating margin rising 145 to 195 basis points, reaching a range of 27.75% to 27.75% — that is, between 27 and one quarter and 27 and three-quarters percent. Most of that adjusted gross margin gain will flow from the gross margin line, combined with better OpEx leverage than last year. As we've said before, we pulled some OpEx spending forward into 2019. Looking ahead to 2020, we expect to leverage our cost structure more effectively, both on the UroLift side and in our base business. Last, the HPC acquisition should provide a modest tailwind at the adjusted operating margin line. So that brings us to what we're expecting for adjusted EPS in 2020; the slide you're looking at walks from where we landed on a full-year adjusted EPS basis in 2019 over to what we're projecting for full-year 2020. We start at $11.15 in adjusted EPS for 2019. On the operating side, for 2020 we're looking at incremental earnings somewhere between $1.92 and $1.99 per share, which works out to growth somewhere in the 17% to 18% range. Woven into that guidance is a $0.06 hit tied to sterilization; what we anticipate is meaningful operating leverage coming from top-line expansion, a better mix, and efforts to bring manufacturing costs down. When it comes to interest expense in 2020, our expectation is a range of $70 million to $73.5 million; baked into that is the assumption that we'll use our revolver to fund the HPC acquisition at the outset, then take those revolver borrowings and term them out later in 2020. We see that lower interest expense versus the prior year adding somewhere between $0.09 and $0.16 of accretion to earnings. Now on to taxes. For 2020, we're projecting an adjusted tax rate falling somewhere between 13% and 14%, which translates into a headwind to adjusted earnings per share of between $0.27 and $0.42. That projected rise in the adjusted tax rate compared with last year stems from a larger anticipated share of U.S. taxable income, driven mostly by growth in UroLift. On top of that, we're assuming the 2020 windfall benefit from stock-based compensation comes in at a more normalized level, unlike the unusually high level we saw in 2019. Now let's move to share count.

Thomas Powell

executive
#4

Our projection is that weighted average shares for Full Year 2020 will rise to 47.5 million, creating dilution of roughly $0.11. Turning to FX, if we assume a euro to dollar exchange rate of $1.11 across the full year, FX should act as a headwind of about $0.10. And lastly, we've included a headwind of between $0.05 and $0.10 tied to the coronavirus. Even with these various headwinds, our adjusted earnings per share outlook of $12.50-$12.70 remains strong, reflecting growth of between 12.1% and 13.9% compared to 2019 — a rate of growth that's roughly twice what we expect for as-reported revenue growth. It isn't our custom to give specific quarterly financial guidance, but at the start of each year we have made it our practice to call out certain considerations about variability in our quarterly expectations. Starting with selling days: 2020 has one more day than 2019, since the first quarter has one fewer day while the fourth quarter has two additional days. As in 2019, our guidance assumes we'll achieve roughly 22.5% of full-year reported revenue and roughly 19.5% of full-year adjusted earnings per share in the first quarter of 2020. These figures reflect our expectation that Q1 will take a $5 million-$7 million hit from sterilization, plus $5 million-$10 million from the coronavirus. On top of that, we expect FX impacts to be largest in the first quarter. Looking at adjusted EPS, the sterilization item together with the coronavirus should reduce Q1 results by $0.11-$0.16. And finally, first quarter revenue profitability will take a negative hit from one fewer selling day, which we estimate at $9 million in revenue impact. Partially offsetting these Q1 headwinds will be a partial quarter benefit from the HPC acquisition. That wraps up my prepared remarks. I'd now like to hand the call back to Liam for closing commentary.

Liam Kelly

executive
#5

Appreciate it, Tom. To wrap up, there's a lot about 2020 that has us energized at Teleflex. Our projection is as-reported revenue growth somewhere in the range of 6.5% to 7.5%, with constant currency revenue growth falling between 7.2% and 8.2%, and roughly 1.2% of that coming from buying HPC. Even with some challenges we're facing, we anticipate yet another year of robust adjusted earnings growth — one that comes in at roughly twice the pace of the as-reported revenue growth we're forecasting. As we look ahead toward 2021, our confidence remains solid that we can achieve constant currency revenue growth of 6% to 7%, while our adjusted gross and operating margins climb to ranges of 60% to 61% and 30% to 31%, respectively. That brings my prepared remarks to a close. At this point, I'd like to hand the call back over to the operator so we can begin Q&A.

David Lewis

analyst
#6

Good morning. Liam, I want to start by discussing growth, and then maybe a quick follow-up question regarding China. When we look forward to 2020, your guidance and some of the key factors — I noticed UroLift was responsible for fifty percent of the company's expansion in 2019. For 2020, you're guiding at 25%. That marks a significant decline from the 50% exit rate. You've mentioned that for you this year, the difference between 25% and 35% growth amounts to a full point of growth. So, I suppose, please explain the 2020 investments and why such a dramatic slowdown in growth would be plausible. David, while we're on this topic, could you give us some idea, Liam, of what you expect MANTA's market share to be in 2020? I also have a quick question about China to follow up.

Liam Kelly

executive
#7

Sure thing, David. I'll start by talking about how Teleflex grew in 2019, both with UroLift and without it. At constant currency, our overall growth was 8.1%. UroLift contributed about 4% of that, while the remaining business contributed about 4.2%. David, please remember that we experienced a sterilization impact of roughly 30 basis points. If you adjust for that, growth in the rest of the business would have been 4.5%. Whenever we start a new year, we've tended to be quite cautious. I've frequently mentioned that with UroLift, our position is shifting from the initial adopters to those who follow quickly. Because of that, we've consistently expected that getting this fresh group of physicians involved would require somewhat more time. Even so, throughout 2019 our performance has been exceptionally strong. The demand picture in our markets remains the same. And like we said earlier on today's call, a national direct-to-consumer pilot is planned for 2020, which in our view could give that product a boost by getting more men to understand that a permanent fix exists that doesn't cause sexual dysfunction for the condition they're dealing with. How the year unfolds remains to be seen, though 2019 was an outstanding one for it. As you know, UroLift kept gaining momentum throughout the year and, frankly, outperformed everything we had projected as it scaled up. Particularly during Q4, reaching 54.4% was impressive given that they faced their hardest year-over-year comparison. That kind of performance shows great execution, and it confirms we made the right call holding off on bringing UroLift 2 to that sales team during the fourth quarter, letting them instead concentrate on growing revenue faster. Regarding your other point about MANTA, we finished the limited market release in Q4 and moved to a full launch starting January 1st. Customers continue to respond very positively, and reorders are coming in at a strong pace. Thanks to how we combined a limited market release with ongoing expansion across the EMEA region, we reached 4% penetration of our $200 million-$300 million target market during 2019, and for 2020 our expectation is 8% penetration of that same market. As you're aware, the clinical data is excellent: a 70% drop in vascular complications, plus mean time to hemostasis falling from six-10 minutes, 23 seconds. That product has us quite enthusiastic too. David, I believe that covers everything you raised. Have I?

David Lewis

analyst
#8

You certainly did, Liam. I just have one brief question about China. I appreciate what you shared regarding how the coronavirus is affecting China in the first quarter. But stepping back a bit, Liam, several competitors — and a few that aren't exactly direct rivals — have been discussing how pricing in China is developing for 2020 and afterward. One of the companies you compete with in peripheral catheters, for instance. Could you speak about your portfolio in China, and how you feel about tenders there and what pricing pressure means for your business looking at this year and the next one? Many thanks.

Liam Kelly

executive
#9

Yes. Thanks, David. Truly, when we're choosing which products to bring into China, we are extremely selective. If you recall our Analyst Day, a number of investors found it somewhat surprising that Asia Pacific gave us the highest gross margin among all our regions. A major reason for that is the specific products we sell in China; we offer the top tier of our surgical products; we offer our coated CVCs, we offer our intra-aortic balloon pumps, and we offer our laryngeal mask portfolio. Every one of those is highly differentiated and extremely difficult to replicate. That's why I think our portfolio in that respect, at least, is somewhat distinctive, and we haven't experienced the same pricing pressure that we're aware other businesses have described. I attribute it to the portfolio we offer; we sell very few Foley catheters, for instance, since in any region where you'd be selling those, you'd face 50 competitors. But when you're selling coated CVCs with antithrombogenic and anti-infectious protection, no one else competes in that space, so you aren't subject to the same pricing pressure. Our selectivity regarding the portfolio we sell in China, David, is genuinely serving us well when it comes to that pricing pressure others are encountering.

David Lewis

analyst
#10

Great. Thanks so much.

Liam Kelly

executive
#11

Thank you.

Larry Keusch

analyst
#12

Thanks. Good morning, everyone.

Liam Kelly

executive
#13

Morning.

Larry Keusch

analyst
#14

So, to kick things off, and perhaps this is aimed at Tom — and Liam, I believe you might have touched on this during your prepared remarks — but the bottom line here is that you all continue to express confidence in your capacity to reach the margin objectives outlined in the LRP. When I examine what you've presumably factored in for 2019, at the midpoint of that range, it comes to roughly 170 basis points. That would suggest a pickup exceeding 200 basis points of expansion come 2021. Once again, could you walk us through how you're viewing that 30%-31% range and what bridges the gap from where we stand today to that level.

Thomas Powell

executive
#15

Sure. As I see it, when we examine the primary forces behind our margin improvement, the bulk will stem from the product mix — specifically high growth, high margin offerings such as Interventional Urology, Interventional Access, Vascular Access, and MANTA — plus the advantages stemming from the footprint restructuring program we announced earlier. Those represent the main contributors to gross margin, and from there it flows through to operating margin. And when we turn our attention to op margin, what stands out is that even with the spending behind UroLift, we keep witnessing its op margin climb sharply thanks to our improved ability to leverage the cost structure; we anticipate seeing even more of that benefit as the business keeps expanding and possibly the investment level won't be as elevated as it was during 2019. Basically, our expectation for 2021 is that these same forces carrying 2020 forward will persist — namely the mix of high growth, high margin products, gains from restructuring initiatives, and cost structure leverage across both the base business and UroLift. Those, I'd say, are the essential pieces, and from our vantage point, UroLift will serve as a key catalyst for our margin expansion.

Larry Keusch

analyst
#16

All right, great. So perhaps regarding that topic, for UroLift and for Liam — Liam, this might be a few questions rolled into one, but could you share some details about the additional sales staff you've managed to bring on board as we head into 2020 within the U.S.? What's the current status of your efforts to establish the infrastructure over in Japan? And also, between receiving reimbursement and actually getting operations fully running there, what steps are required? My understanding is that a study following both approval and reimbursement needs to be completed. Thanks.

Liam Kelly

executive
#17

Larry, I appreciate that. Let's begin with the U.S. sales team — roughly 20 sales representatives came on board during Q4 of 2019. Initially, we figured we'd bring them in around this time. We moved that up so we could kick off the year with a settled sales organization, with every territory in alignment and the group performing at a strong level, just as they have since our acquisition. This operation keeps surpassing what we anticipate, Larry. As for Japan, our expectation remains that we'll be bringing in revenue during 2021. We foresee securing reimbursement clearance in the second half of 2020, which would allow us to produce revenue in 2021; we've invested ahead of time, and we currently have personnel on the ground, Larry, carrying out market development activities in Japan at this very moment, and we had them there during 2019. As we reach the back end of 2020, a bit of extra spending will be needed to guarantee that revenue generation begins in 2021. When it comes to modeling Japan's revenue, Larry, I'd request that you focus on 2021 instead of 2020, and that's the message we've consistently communicated to the investment community. Concerning the post-reimbursement situation, yes, there's a need to collect certain data, and we've got the necessary infrastructure ready to handle that and then deliver it to the government. That won't hold back the revenue growth, Larry. It's a database where we keep gathering information across North America as we expand, just as we did throughout 2019.

Larry Keusch

analyst
#18

Okay, that's great. Thanks a lot.

Liam Kelly

executive
#19

Thanks.

Richard Newitter

analyst
#20

Hello, and thank you for allowing me to ask. Two things from me: first about UroLift, and second regarding the acquisition you completed and how it aligns with your long-range plan. Perhaps starting with UroLift, Liam — is the correct takeaway here that every signal points to things only improving where momentum is concerned, yet, as David inquired earlier, the guidance you've given suggests a fairly meaningful slowdown? Is the basis for that essentially just the presumption that this shift toward middle adopters — something you've honestly expected and prepared for across many consecutive quarters without it really materializing, which has held back growth? That's your working premise: it will arrive in 2020. Should it fail to arrive, then presumably growth ought to accelerate. Am I correct in framing what's behind that deceleration against what you're truly observing, and that gap between the two? Is that the proper lens?

Liam Kelly

executive
#21

Yes, Rich, good question. Look, Rich, our end markets haven't shifted at all, and there's no major bogey sitting out there. Let me begin with that. Nothing about that business concerns Liam Kelly. Second, each year when it starts, we consistently remain fairly cautious regarding the shift from early adopter to fast follower. We've attempted to counterbalance that through hiring additional sales reps, and over the past couple of years that appears to have worked. As you'd sometimes have requested of us, we're attempting to be somewhat careful right at the outset in case moving early adopters to fast followers produces an impact. From the Teleflex team's standpoint, there's no significant concern when it comes to the end markets. In fact, during this quarter I was on the road for an entire week meeting urologists, speaking with them regarding the DTC we planned to introduce and requesting that they prepare. What we require as we run this test national DTC is the catcher's mitt. I have to say, the urologists I encountered showed tremendous enthusiasm. Over one week, I believe I met roughly 15 urologists. There was considerable excitement regarding what we were doing with the DTC campaign. In my view, the responsibility falls on Teleflex to educate men that the UroLift product represents a solution for treating BPH. According to our research, among men who have BPH and are receiving a urologist's care, merely around 5% or 6% know that UroLift is an option. That's an issue we believe must be tackled, and we must boost awareness among men regarding this treatment choice that involves no sexual dysfunction. That, I believe, is how we see it at present, Rich. Naturally, we'll keep refreshing things as the year unfolds.

Richard Newitter

analyst
#22

Appreciate the additional detail, Liam. To build on that regarding the acquisition and how it ties into your long-range plan, how does HPC's top line growth look? My assumption is that it adds to growth; given the 6%-7% long-range plan, which assumes no acquisitions, and the 30%-31% operating margin target by 2021, could this deal move you toward the mid to upper end, or in what way does it influence your ex-acquisition long-range plan guidance metrics? Thanks.

Liam Kelly

executive
#23

Yeah. I believe your point is correct. Our long-range plan did not account for acquisitions. To be fair, Rich, it also didn't account for tariffs, FX, the coronavirus, or sterilization. We've gotten past each of those hurdles while surpassing our long-range plan by delivering stronger top-line growth and better earnings per share than we had expected. As with any long-range plan, there are headwinds and tailwinds. This wasn't part of our long-range plan. You're entirely right; it adds to our top-line growth. It's in fact accretive to OEM's top-line growth, and it also adds to our op margins. That's clearly why we were eager to secure this. More significantly, I believe for our OEM business, it places us in a very attractive area; it brings us into the thin-walled, wire-reinforced catheter space, which is expanding quickly since this is the direction the catheter space is heading. Catheters need to become smaller, and then they need greater torque. Whether you're doing neuro procedures, interventional radiology, interventional cardiology, structural heart, peripheral, and EP procedures, this is the kind of technology you have to have. It was a hole in our OEM business, and we're delighted to have filled it only a couple of days ago.

Richard Newitter

analyst
#24

Thank you.

Liam Kelly

executive
#25

Thanks, Rich.

Shagun Singh

analyst
#26

Thanks a lot for taking my question. I'd like to discuss how well UroLift did in Q4. Could you provide some figures for us, like the utilization rates among the customers you currently have, how much growth you're seeing in bringing new customers on board, and also the DTC initiative? On the DTC initiative specifically, Liam, I think you'd mentioned you were aiming for a critical mass of trained physicians, roughly 6,000. This news arrives somewhat sooner than anticipated. Could you say more about taking the DTC initiative nationwide? What scale will it reach? Should it perform well, would you intend a full launch during 2021? Usually, that's tied to a significant increase in growth. Any details would be useful.

Liam Kelly

executive
#27

All right. That's quite a bit to address, Shagun. I'll attempt to cover as much as possible; regarding your first point, roughly 60% of the growth we see keeps coming from customers we already have, while 40% comes from new ones we add. I can say that ever since we made this acquisition, we've kept observing same-store sales climb each quarter, quarter after quarter. One of the things we track is same-store sales and the way they climb. As for the part of your question about DTC, we did want a catcher's mitt, Shagun, yet at the same time, we didn't want to tip off our rivals that this was something we were considering. That's the reason we were somewhat more coy than usual while discussing it. After stepping back and analyzing our geographic coverage, we feel we have enough trained urologists in place so patients can locate a urologist in every region of America once the DTC campaign begins. Looking back to 2018, we ran six regional DTCs. During the past year, we ran 16 DTCs. We've actually built a solid knowledge base regarding direct consumer campaigns; it will combine television campaigns aimed at certain cable channels, CNN, Fox News, The Golf Channel, and so forth. A larger portion will focus on complementary digital efforts like Facebook ads, Google, PPC, WebMD, and all those sorts of places. We're really eager to start this pilot. It will begin in Q2, and we'll track the results. What we learned from our regional campaigns was that we saw a good uplift in men pursuing treatment for BPH in those locations. Should the national campaign produce that same outcome, then we'll weigh our options, Shagun, about expanding it more widely in later 2020 and into 2021. That would be backed by the revenue growth the campaign would generate.

Shagun Singh

analyst
#28

Understood. Thanks. Let me ask one more thing. With UroLift 2.0, there's an opportunity for roughly 400 basis points of gross margin expansion. My understanding is that launch won't happen until May 1st, since you're implementing certain visualization modifications. Liam, can you explain what those modifications involve? Tom, regarding the shift to gross margin, how much of the favorable effect ought we to anticipate during the second half of 2020? Thanks for fielding the question.

Liam Kelly

executive
#29

Sure thing. Yes. Based on input from our urologists, we made a few modest adjustments to the product. Our goal is simply for this product to be flawless. The UL1 enjoys such an enormous reputation among urologists. In every respect, we want the UL2 to be flawless, and we think this modest adjustment will in fact even assist adoption in moving faster. We have confidence about launching that product, securing the 510 during Q2, and starting to perform some procedures. That's among the reasons why a portion of our margin expansion is somewhat back-end loaded into 2021, since that is when the bolus of the conversion will occur. I'll let Tom cover the details on that.

Thomas Powell

executive
#30

Well, I'd say that's the correct manner of looking at this — we're anticipating having UL 2 available around the middle of this year. The genuine advantage should show up during 2021; for 2020, what we're putting into our model is only slight gains stemming from that switch getting underway.

Shagun Singh

analyst
#31

Thank you so much.

Liam Kelly

executive
#32

Thanks, Shagun.

Matt Taylor

analyst
#33

Hi, and thanks for taking my question. I'd like to dig a bit deeper into what's happening with sterilization. A month or two back when we spoke, my impression was that the bulk of this was on track to be settled. I just want to get a handle on what new developments have come up regarding your projection for the sterilization headwind. Which factors might make that turn out stronger or weaker than what you're anticipating this year?

Liam Kelly

executive
#34

Matt, let me start off by noting that the effect of the sterilization capacity situation is already factored into the 2020 guidance we put out today — that's the first point. During our prepared remarks, we mentioned that we anticipate a revenue hit of $5 million-$7 million, along with an EPS impact of roughly $0.06. Surgical OEM, plus the other category within our urology products, are the product categories affected. What we found as we moved into the early part of the first quarter was that revalidating certain cycles took longer than we'd expected, so we've got a bit of a carryover into the first quarter. That figure is $5 million-$7 million. For a company of our size today, that's not a particularly large impact. As I see it, the gating factors are these: we've still got one cycle left to complete, and revalidation ought to wrap up in early March, which we fully expect to occur. We're feeling fairly confident about the estimate currently in our plan that we've baked in. It does land in the first quarter. Matt, if you'll give me a moment, there's a broader point I'd also like to raise — in the first quarter we're facing two impacts plus one fewer billing day. Looking across the year, once corona sterilization and that day are behind us, here's what you'd anticipate seeing over the course of the year: you'd anticipate MANTA ramping. You'd anticipate UroLift carrying on demonstrating robust growth, as would Vascular APAC and OEM. Clearly, we'd have that acquisition recorded within the OEM business. Then, as the year progresses and you reach quarter four, you gain that one billing day, plus one more billing day in the fourth quarter, which would carry a revenue impact. Thanks for letting me go into more detail there, Matt.

Matt Taylor

analyst
#35

Mm-hmm. Thanks, Liam. I suppose I was simply hoping you might take another minute to discuss the acquisition. For an OEM business, that's a pretty meaningful multiple. I was just wondering whether you could address the capabilities you're bringing online. Is that merely something you'll be able to expand alongside certain growing categories in OEM, or could you actually take the capabilities and products you produce from that acquisition and launch your own products? Could you speak a bit more about what the outlook looks like for that business?

Liam Kelly

executive
#36

Yes, absolutely. First regarding the multiple, Matt, you're clearly working it out based on revenue. I'll tell you, on adjusted EBITDA it's a highly attractive multiple. I think we view this as an OEM acquisition meant to bring capability into that OEM business; a few years ago we purchased a small OEM business known as Cartica, and what we found after that acquisition was that it was a win-win. We could leverage their customer base to speed up some of our growth, and the reverse as well, then take our customer base and leverage their product portfolio; it's the same play here again. As I mentioned earlier, these smaller thin-walled reinforced catheters represent the fastest-growing space in the catheter business within the OEM space. So, we anticipate this business will be accretive to even OEM's growth, not to mention Teleflex's.

Matt Taylor

analyst
#37

Great. Thanks, Liam.

Liam Kelly

executive
#38

Thanks, Matt.

Anthony Petrone

analyst
#39

Thanks. Perhaps a couple of fast questions from my side. Regarding UroLift, I'm curious about the share of the market that the larger prostate indication truly unlocks, and therefore how significant a gain that particular indication will deliver going forward. The second one concerns MANTA. On that outlook, Liam, I'm somewhat curious about what's assumed for the lowest TAVR indication, plus new TAVR centers becoming active after the NCD. I believe the last time we talked, those weren't included in the long-term guidance. Thanks.

Liam Kelly

executive
#40

You cut out a bit at the end.

Thomas Powell

executive
#41

When we last spoke, the low-risk TAVR was not necessarily considered in.

Liam Kelly

executive
#42

Okay

Thomas Powell

executive
#43

market size for long-range guidance.

Liam Kelly

executive
#44

Alright, thank you, Anthony. To start, let's turn to UroLift. Roughly 3%-5% of the patient population would be covered by it. My view is that this would grow the market to that extent. Another way to think about it: previously, when a urologist scoped someone and found a bigger prostate, they might have chosen a TURP or some other route. This simply grows that market, and it makes things simpler for the fast followers. It takes away one more objection for our sales team. As for MANTA, we continue to assume the market sits at roughly $200 million-$300 million. We haven't broadened that for the low-risk TAVRs, which could bring in an additional 10% at both the bottom and the top end, Anthony. Based on what we know right now, with 690 TAVR centers across the U.S., from our fact-finding and our limited launch, we know training an interventionalist requires 10 cases — five proctored plus five observed. A busy center handles about 300 cases. We believe we've been careful in how we've structured this. We have 4% of — let's use the midpoint, so let's use $250 million. We've reached roughly 4% of the global market, and by the close of this year, our plan is to reach 8%. That's our target, and clearly, once again, we'll provide updates as we make progress; we couldn't be more thrilled about that MANTA product. It's performing very well out there, and customer feedback has been highly positive.

Anthony Petrone

analyst
#45

Wow. That's helpful. Thanks.

Liam Kelly

executive
#46

Thank you.

Matthew Mishan

analyst
#47

Morning, and thanks for taking my questions. Hey, Liam. UroLift showed sequential acceleration, yet the two other drivers of sustained growth for Teleflex in my view, interventional and Asia, both slowed on a sequential basis as the year went on. I'm just trying to get a handle on what caused that slowdown. Is the GuideLiner portfolio losing some momentum within interventional? Or are we simply in an interim stretch while MANTA ramps and the <<inaudible>> approval comes through?

Liam Kelly

executive
#48

Yeah. To start with, within our complex catheters, the segment where GuideLiner gets booked, no deceleration has appeared at all. It truly delivered a very strong year. I wouldn't spend much worry on interventional, Matt. A few factors are at play. Our intra-aortic balloon pumps get booked in that business. Those intra-aortic balloon pumps enjoyed a really strong Q1 and Q2, and a solid Q3. Capital spending came in somewhat light during the fourth quarter. Although that business expanded in the mid-teens during the fourth quarter, it landed in the low singles. That's one dynamic. Another major dynamic in that business is that the business we divested posted a really strong Q4 a year ago. I believe it came to roughly $3.5 million. Year-over-year, you're up against a tough comparable from that business. Those are the two businesses. I couldn't be happier with that business. That interventional business grew 10%. All year we'd been saying it would like to hit the high singles or sneak into the doubles, and I'm really pleased with how it performed. As for Asia, it was pretty much in line with what we wanted as well. It grew 7% on a full-year basis. During the fourth quarter, we did see a bit of softness in Australia, New Zealand, and in India. Just end-of-year items that didn't arrive as fully as anticipated, though not by much. A very modest surprise in those two areas is how I'd describe it.

Matthew Mishan

analyst
#49

All right. My apologies if this was already covered, but could you share the guidance for operating cash flow and CapEx in 2020? And how does that stack up against what you were anticipating under the 2019 to 2021 plan?

Thomas Powell

executive
#50

When we look at cash flow from ops for 2020, our expectation is a range of $485 million, with CapEx around $110. If we compare that to what we had anticipated during the LRP timeframe and the guidance we gave, we're coming in below it for a few reasons. The biggest one is contingent consideration. Because of how NeoTract performed, in 2020 we'll be paying roughly $80 million in contingent consideration beyond what had been expected previously — or, put differently, the impact on cash flow from operations is roughly $80 million from that. On top of that, we introduced a couple of new restructuring programs in 2019. The restructuring expense, the cash expense, plus some of the CapEx, comes to roughly $27 million tied to that. Lastly, FX has hit us to the tune of nearly $40 million compared with the LRP expectation; we have a few large factors pushing us below where we had thought we'd be. Obviously, as we move into 2021, the contingent consideration winds down; it will drop significantly from the roughly $80 million this year. That will be a benefit to us when we look at our free cash flow going into next year.

Liam Kelly

executive
#51

All right. Thank you very much.

Thomas Powell

executive
#52

Yep.

Matthew O'Brien

analyst
#53

Thanks. Morning, and I appreciate you taking my questions. Tom, math isn't exactly my strong suit, but could you walk me through the accretion coming from the acquisition? What I'm calculating is slightly above $0.10 of accretion. Part of what I'm hoping to dig into further with that question is the DTC side, given the spending you'll be doing this year, since the guidance range — if you did capture roughly $0.10 of benefit from the deal — comes in a bit under what the Street has modeled. You've got a sizable tax headwind, and on top of that there's this DTC headwind that I don't believe people were anticipating. I'm trying to understand, once you net out some of the puts and takes on the spending side, what EPS growth will look like. Thinking about Z-Medica, did you say you're getting $0.10 of accretion?

Thomas Powell

executive
#54

Slightly more than that, yes.

Matthew O'Brien

analyst
#55

All right. When we consider Z-Medica, I'd describe that as likely exceeding what we had anticipated; our assumption was for a slight amount of accretion. In relation to that, it truly hinges on how we finance it. The speed at which we convert that revolver borrowing into term debt and the interest rate we can secure. I'd characterize that as perhaps a slight variance. Please clarify for me, are you attempting to exclude certain nonrecurring items and calculate an adjusted EPS, or?

Thomas Powell

executive
#56

Yes. So, what is the size of the DTC spend? Once more, I don't believe — since Kelly mentioned you would undertake this somewhat afterward as opposed to a nationwide spend during this year. I suspect the majority of people did not anticipate that. Additionally, the tax rate clearly stands considerably above what you recorded in '19-

Matthew O'Brien

analyst
#57

Yes, once more, with that adjustment taken into account. Just a bit of broad perspective on those items as we consider what the narrative around earnings power looks like.

Thomas Powell

executive
#58

All right. When we consider what will be spent on UroLift during 2020, assuming we examine all digital spending while leaving out DTC, and afterward add DTC on top, that amount would reflect roughly a $2 million increase compared with our 2019 outlay.

Liam Kelly

executive
#59

Matt, here's how I'd frame it: the sole EPS headwinds nobody saw coming are the ones we called out. Everything else had already been factored in while we put our plan together. There's the coronavirus, which wasn't something we expected, plus the sterilization, which we also didn't expect. Combine those two and use the midpoint, and you land at roughly $0.10 or $0.12 from them. Both will land in the first quarter. On DTC, we're putting more dollars behind it for a national campaign; that's already part of our plan, and it was in our thinking. Now, you're correct. Year over year, spending rises to fund that investment; revenue should feel an effect, and in my view, getting more men informed about this condition will genuinely benefit us over the longer term. Turning to the HPC acquisition, internally we nicknamed it Iceman, which is what Tom mentioned a bit earlier.

Matthew O'Brien

analyst
#60

Absolutely.

Liam Kelly

executive
#61

The acquisition went by that name internally. How accretive HPC turns out to be is modest, and it hinges on the kind of financing arrangement we end up using for it. What has us genuinely enthusiastic about this deal is the technology we gain from it. Taking a broader view, when we consider the sort of business we are working to create — and have already created and continue creating — the idea is this: if top-line growth reaches, say, 6%, then on the income statement we aim to leverage that up so that earnings deliver a 12% return for our investors on the bottom line. That is the goal we are pursuing as we set out our plans across the coming years.

Matthew O'Brien

analyst
#62

Understood. Let me ask one quick follow-up. Liam, with UroLift too, I completely get that you'd rather introduce it gradually so it lands flawlessly. Considering the sheer number of clinicians you need to reach with that launch, how should we frame it? I'm sure the rollout stays measured during this year's second half, then picks up somewhat in 2021, but with the meaningful financial effect arriving in the latter part of next year and carrying into 2022?

Liam Kelly

executive
#63

Matt, my expectation is that 2021 will show an impact. The rationale behind wanting everything flawless is that it becomes simpler for clinicians to genuinely take it on board. Here's how things function in the field alongside our sales reps: they aren't present in every single case, clearly, yet roughly once per month they make a milk run back to a urology practice, confirming patient outcomes are adequate, checking that no problems with the product have arisen, and ensuring they stay in touch with the key customer. During such a milk run, a typical urologist requires five cases in order to be trained. Since urologists tend to stack cases, that amounts to one day's work. My view is that the modifications we've implemented ought to smooth the path to adoption. Beyond that, it cuts down their clinical waste, which ought to assist in boosting margins inside the office or the ASC; it also shrinks our carbon footprint. I'd push back and say you ought to anticipate a margin lift from UroLift 2 during this year's back half, with additional gains arriving in 2021, Matt.

Thomas Powell

executive
#64

If I return to that initial inquiry you raised regarding earnings power. I believe page 14 does a good job of illustrating several elements you might apply when attempting to modify for certain of those headwinds. Beyond that, you would also want to factor in the sterilization effect, which we identify at roughly $0.06. Once more, regarding the HPC acquisition, the timing and manner in which we complete it will influence how accretive it becomes. As Liam mentioned, it is modestly accretive in 2020. Page 14, I think, provides the key points for you to take into account.

Matthew O'Brien

analyst
#65

Appreciate the color. Thanks.

Thomas Powell

executive
#66

Yep.

Liam Kelly

executive
#67

Thanks, Matt.

Chris Cooley

analyst
#68

Morning, and thanks for letting me ask a few things. I've got a couple of quick administrative items, and then one point I'd like clarified. From an administrative standpoint, leverage on a pro forma basis currently sits at roughly 2.7x, which is somewhat higher than before. I'm just wondering how you view deploying cash flow going forward, along with your coverage ratio. In a similar vein, regarding EZ-Pause, my understanding is that previously you were hoping to speak with the agency ahead of today's call. Could you provide an update on where that stands? Many thanks.

Liam Kelly

executive
#69

Of course, Chris. I'd be failing in my duty if I didn't mention that working with the FDA has gone extremely well. Everyone here is quite enthusiastic about this product, since we're all aware of the benefits it could deliver both for the military and for civilians. All of the testing mandated by the FDA has now been finished. You're correct, Chris. Our hope had been to sit down with the FDA prior to today's meeting. In March, the FDA requested that we hand over the full data set, and our meeting with them is now set for April. That's where the schedule stands at present. We've kept navigating these uncharted waters, though I'm quite pleased with how this product is progressing. My expectation is that the April meeting with the FDA will clarify, at minimum, how we're thinking about timelines for the BLA submission. That meeting is something we're eager for. Your second question concerned leverage and how we use capital. As today's HPC announcement showed, we've kept putting our capital toward strong strategic long-term M&A at 2.7x net leverage. There's still room on our balance sheet, we remain active, and assets we'd have interest in are still available. For the moment, continuing to pursue really good M&A would be our preferred way to deploy capital.

Chris Cooley

analyst
#70

Let me squeeze in one more quick thing, if that's all right. I just want to get some clarity here. In an earlier question, I believe you mentioned that just 5%-6% of patients being treated by urologists knew about UroLift. What I'd like to know is whether that figure applies to urology as a whole, or only to the physicians currently implanting the device? Given that these would be active UroLift users, that number strikes me as fairly low for the implanting group. And if you meant the implanters, could you explain why that message isn't reaching people inside those practices?

Liam Kelly

executive
#71

Chris, the patients are who I meant.

Chris Cooley

analyst
#72

Okay.

Liam Kelly

executive
#73

The men that have-

Chris Cooley

analyst
#74

Thanks.

Liam Kelly

executive
#75

Those do meet the requirement. Okay. Appreciate it, dude.

Chris Cooley

analyst
#76

Thank you.

Liam Kelly

executive
#77

Cheers.

Kristen Stewart

analyst
#78

Hi there, and thanks for taking my question. I'd like to circle back a bit to cash flows, and then walk through some of the puts and takes there as well. So when do you expect to see somewhat more strength when it comes to cash flows? From what I can tell, it looks like you folks grasp the accounting for contingent consideration and how that operates, but there also appears to be a lot flowing through tied to certain one-time costs involving acquisition integration and restructuring. On top of that, it seems you have some estimated costs baked in for MDR too; that appears larger than what I would have expected in the 2020 numbers as well. Could you perhaps give a bit more detail on cash flow improvement ahead and what you're expecting there? I have a follow-up. Thanks.

Thomas Powell

executive
#79

Sure. Kristen, I believe you've hit on the fact that the crucial item is contingent consideration along with FX and a few of the new restructuring programs we've implemented. When we consider some of these, the restructuring programs, our cash usage right now, clearly we implemented them since we view that as a longer-term capability to drive margin expansion as well as future cash flow. When we look at where an acceleration will begin to appear, we think that 2021 will demonstrate a marked improvement, and a few of the factors behind that are simply that the level of contingent consideration will decline from roughly $80 million in 2020 to 25 or so million in 2021. We'll also see an increase, obviously, in our net income. As we keep building the business, we've placed more inventory into the channel at present to help with back orders. As we move into the next couple of years, we actually see inventory declining somewhat for two reasons. One is that many of the footprint moves are going to start being behind us, and so the strategic builds to transition from one facility to another will begin to decline; we also have some programs in place to greatly improve our S&OP processes and otherwise to help take down those inventory levels. I'd also say another area where we'll see some improvement is simply in CapEx. Our CapEx has been elevated in 2019 and 2020, partly because of the manufacturing footprint moves and having to fit out those new locations. Those are the key areas that we'll look to see driving future cash flow growth. really, 2021 is a year where you should see some nice acceleration relative to what we see in 2019 and 2020.

Kristen Stewart

analyst
#80

And regarding the MDR expenses? For 2020, those look quite elevated. Is this more or less a single occurrence, as you bring things into line with the fresh rules?

Thomas Powell

executive
#81

Actually, this is a program spanning several years. Compared with 2019, we certainly carry a sizable cost in 2020, yet that will continue for two or so additional years while we complete the rollout.

Kristen Stewart

analyst
#82

Okay. Thank you very much.

Thomas Powell

executive
#83

Yep.

Dave Turkaly

analyst
#84

Thank you. I'll ask a couple of fast ones. To begin, you pointed to a decline in how frequently U.S. distributors are ordering in anesthesia. I was curious whether you could shed light on what's behind that and when it turns around. Second, I'll just put it out there right away. In Asia, I believe you pointed to price hikes as accounting for most of the 2.7% CC gain. I was wondering whether you could explain why you managed to achieve that and precisely where that net price is coming from. Thanks.

Liam Kelly

executive
#85

Let's begin with the pricing. The expansion in Asia Pacific during the quarter was, as you say, 2.7%, but I don't believe we claimed that was entirely That's largely volume. the volume of our interventional access and our vascular access products is really what's generating that growth there. Across the enterprise, for the company over the full year, you're right, we did achieve roughly 30 basis points of positive pricing as an organization. That's really originating from a handful of areas. Our surgical business seized a one-time pricing opportunity that allowed it to generate some pricing in our vascular business, in our interventional business, and in Asia PAC, pricing was positive. Negative pricing typically shows up in respiratory and in EMEA, but when you total it all, it came out positive this year at roughly 30 basis points, Dave. The second half of your question concerns the ordering behavior. What we observed in anesthesia was $2million- $3 million of de-stocking during the fourth quarter; that usually returns. I think that across the full year, we did experience some de-stocking as an enterprise from these distributors; it has a smaller effect for Teleflex now, Dave. That's simply because historically, our business went through these distributors and today only one-third does. It's a modest effect on Teleflex overall in the fourth quarter, with the majority of it residing in anesthesia.

Dave Turkaly

analyst
#86

No, I appreciate it. What I was asking about was the remark on purchasing patterns as opposed to the timing. Thanks for clarifying that.

Liam Kelly

executive
#87

Fine. No problem at all.

Mike Matson

analyst
#88

I appreciate you answering my questions. The majority of what I wanted to ask has already been covered, though I have a few additional ones regarding the DTC campaign for UroLift. First, regarding timing, after you've run the trials with the advertisements, what is the lag between the ads airing and that showing up in your revenue? I'm curious whether there might be an uptick in spending on the front end before it begins flowing through to growth. Second, you said it boosts awareness of BPH overall, which clearly will lead more patients to seek UroLift, yet it could also draw additional patients toward the competitors. Do you believe you can direct them toward UroLift rather than some of the alternative options available? Thank you.

Liam Kelly

executive
#89

We'll take the final one first. Our objective, Mike, isn't to spend on DTC to benefit our rivals. That's my opening point. The advertisement will zero in heavily on certain distinctive aspects of the UroLift offering, and it truly traces back to the entirety of the clinical data available. No other option exists that a patient can be given which carries zero new onset of sexual dysfunction, and that will serve as a central message delivered to the audience. Certainly, what occurs in actual practice is that when a patient visits the urologist and the urologist performs a scope on that patient, should their bladder problems outweigh their prostate problems, to the extent that a TURP becomes necessary, that scenario could arise. In fact, Mike, that won't pose an issue for us at Teleflex. Provided the man receives the optimal treatment choice for achieving the best result possible, that's acceptable. We've observed through our regional DTCs that most patients qualify for the UroLift product, and my expectation is that nothing will change once we expand nationally. As for the typical duration, it largely hinges on the urology practice. After the man connects with the urology practice, you'd anticipate the procedure being booked somewhere in the range of four to six weeks. Past six weeks, based on what we've heard, the dropout rate tends to rise; we're in communication with the urology community to ensure they're geared up and prepared for this campaign, and that's been our effort since the start of the year.

Mike Matson

analyst
#90

Great. Thank you.

Jake Elguicze

executive
#91

Thanks, operator, and I appreciate all of you who took part in today's call. That brings us to the end of the Teleflex Incorporated fourth quarter-

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.